Get the Stockscreener App
1.60
3.90%
0.06
Ikena Oncology Inc stock is traded at $1.60, with a volume of 157.09K.
It is up +3.90% in the last 24 hours and down -7.51% over the past month.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
See More
Previous Close:
$1.54
Open:
$1.55
24h Volume:
157.09K
Relative Volume:
0.96
Market Cap:
$77.21M
Revenue:
$9.16M
Net Income/Loss:
$-68.17M
P/E Ratio:
-0.9412
EPS:
-1.7
Net Cash Flow:
$-80.16M
1W Performance:
-4.19%
1M Performance:
-7.51%
6M Performance:
-3.03%
1Y Performance:
-18.78%
1-Day Range:
$1.55
$1.62
1-Week Range:
$1.495
$1.7134
52-Week Range:
$1.22
$2.07
Ikena Oncology Inc Stock (IKNA) Company Profile
Name
Ikena Oncology Inc
Sector
Industry
Phone
857-343-8292
Address
50 NORTHERN AVE., BOSTON
Compare IKNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.60 | 77.21M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
399.35 | 102.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.59 | 77.21B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
619.96 | 37.07B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.01 | 30.44B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
112.58 | 26.99B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| May-04-23 | Resumed | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Jefferies | Buy |
| Apr-20-21 | Initiated | William Blair | Outperform |
View All
Ikena Oncology Inc Stock (IKNA) Latest News
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Inmagene takes back-door route to Nasdaq listing - The Pharma Letter
Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Purchased by Fmr LLC - Defense World
Ikena Oncology Enters into Merger Agreement with Inmagene BiopharmaceuticalsOn December 23, 2024, Ikena Oncology, Inc. (NASDAQ: IKNA) announced a significant development as it entered into a Merger Agreement with Inmagene Biopharmaceuticals. - Defense World
**FibroBiologics Enters Standby Equity Purchase Agreement for $25 Million Financing** ** - Defense World
Boston biotech opts for reverse merger with San Diego company - The Business Journals
Ikena Oncology and Inmagene Announce Merger and Fundraising - Yahoo Finance
Ikena Oncology (NASDAQ:IKNA) Receives “Neutral” Rating from Wedbush - Defense World
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding - Marketscreener.com
Ikena Oncology's (IKNA) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Ikena Oncology Merger with Inmagene Biopharmaceuticals and Private Placement Financing - Leerink Partners
Ikena Oncology Shares Rise After Merger Announcement With Inmagene Biopharmaceuticals - MarketWatch
Ikena Oncology and Inmagene Biopharmaceuticals announces merger - MSN
Ikena Oncology, Inmagene Biopharmaceuticals to Merge - MarketWatch
iKena Oncology, Inmagene enter definitive merger agreement, private placement - TipRanks
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - GlobeNewswire
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding from a group of investors - Marketscreener.com
Questor Technology (OTCMKTS:QUTIF) Trading Down 13% – Should You Sell? - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update - MarketBeat
Ikena Oncology FY2024 EPS Estimate Boosted by HC Wainwright - Defense World
Ikena Oncology FY2024 EPS Forecast Lifted by HC Wainwright - MarketBeat
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Earns “Buy” Rating from HC Wainwright - Defense World
Ikena Oncology (NASDAQ:IKNA) Given "Buy" Rating at HC Wainwright - MarketBeat
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) - Yahoo Finance
Wedbush Reaffirms “Neutral” Rating for Ikena Oncology (NASDAQ:IKNA) - Defense World
Ikena Oncology Reports Strategic Realignment and Financial Performance - TipRanks
Ikena Oncology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Ikena Oncology Reports 41% Lower Net Loss, Strong $138M Cash Position in Q3 | IKNA Stock News - StockTitan
Renaissance Technologies LLC Sells 300,200 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Point72 Asia Singapore Pte. Ltd. Invests $75,000 in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology’s Gamble: Slashing Workforce by Half Could Derail Strategic Plans - TipRanks
Point72 Asia Singapore Pte. Ltd. Purchases Shares of 45,520 Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Acadian Asset Management LLC Has $536,000 Stake in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Analyzing Ikena Oncology (NASDAQ:IKNA) & Kiromic BioPharma (NASDAQ:KRBP) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Large Drop in Short Interest - MarketBeat
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Down 10.7% in July - Defense World
On Ikena Oncology ($IKNA) Setting up a Sale - substack.com
Q3 2024 EPS Estimates for Ikena Oncology, Inc. (NASDAQ:IKNA) Lifted by HC Wainwright - MarketBeat
Ikena Oncology, Inc. (NASDAQ:IKNA) Expected to Post Q3 2024 Earnings of ($0.26) Per Share - Defense World
HC Wainwright Reaffirms "Buy" Rating for Ikena Oncology (NASDAQ:IKNA) - MarketBeat
Ikena Oncology (NASDAQ:IKNA) Receives Buy Rating from HC Wainwright - Defense World
Ikena Oncology (NASDAQ:IKNA) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - Defense World
Ikena Oncology Reports Second Quarter 2024 Financial Results - GlobeNewswire
Jacobs Levy Equity Management Inc. Increases Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Jacobs Levy Equity Management Inc. Boosts Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA) - MarketBeat
Acadian Asset Management LLC Raises Position in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Decline in Short Interest - MarketBeat
Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting - Barchart
Ikena Oncology, Inc. (NASDAQ:IKNA) Sees Significant Drop in Short Interest - Defense World
Ikena Oncology expands role of CFO Jotin Marango to COO - Investing.com
Ikena Oncology Inc Stock (IKNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):